Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115069) titled 'Prospective, Dual-Cohort, Phase II Study of PD-L1 Inhibitor Combined with Gemcitabine and Nab-Paclitaxel Followed by Sequential PD-L1 Inhibitor Combined with Irinotecan Liposome, Oxaliplatin, and 5-FU/LV for Conversion Therapy in Borderline Resectable/Locally Advanced Pancreatic Cancer' on Dec. 22, 2025.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Zhongshan Hospital Affiliated to Fudan University
Condition:
Pancreatic cancer
Intervention:
Cohort A:Including locally advanced pancreatic cancer, borderline resectable pancreatic cancer with arterial involvement, and b...